

PROGRAMME AT A GLANCE

THURSDAY 23 FEBRUARY 2012

	HALL I Group A	HALL II Group B	HALL III Group C	HALL IV Group D
8.30-9.30	<p>CLINICAL CASE WORKSHOP Management of 1st line NSCLC after 4 cycles chemotherapy and stable disease Moderator: Sanjay Popat Discussants: to be announced</p>	<p>CLINICAL CASE WORKSHOP Decision making in the treatment of recurrent ovarian cancer Moderator: Jonathan Ledermann Discussants: Management of end-stage recurrent ovarian cancer Marcia Hall About surgical aspects of recurrent ovarian cancer treatment Philipp Harter</p>	<p>CLINICAL CASE WORKSHOP Breast cancer Moderator: Stephen Johnston Discussants: to be announced</p>	<p>CLINICAL CASE WORKSHOP Decision making in prostate cancer progressing on ADT Moderator: Chris Logothetis Discussants: to be announced</p>
9.30-11.30	<p>ESSO SPECIAL SESSION Surgical treatment of metastatic cancer Chairs: Graeme Poston and Bernard Nordlinger Speakers: Liver metastases: resection vs. Ablation Theo Ruers* Lung metastasis resection Tom Treasure Peritoneal metastases Dominic Elias Resection non-CRC/non-NET Rene Adam*</p>		<p>ESTRO SPECIAL SESSION New trends in practicing radiation oncology Chair: Harry Bartelink Speakers: Stereotactic radiotherapy for lung cancer Jose Belderbos Translational research in radiotherapy Eric Deutsch* Concomitant radiotherapy and chemotherapy, the standard of care? Jean Bourhis Fractionation schedules in lung and breast cancer John Yarnold Partial breast irradiation state of the art? Roberto Orrechia*</p>	
	SURGICAL ONCOLOGY		RADIATION ONCOLOGY	
11.30-12.00	COFFEE BREAK			
12.00-13.15	<p>CLINICAL QUESTIONS FOR PROSTATE CANCER - SESSION I Chair: Chris Logothetis Speakers: Introduction: New insights in the clinical and basic mechanisms of prostate cancer progression Chris Logothetis Localised Cancer: Changes in the clinical understanding of prostate cancer that frames therapy application Laurence Klotz* Advanced Cancer: The improved understanding of androgen signaling in prostate cancer progression, and its clinical application Eleni Efstathiou Advanced Cancer: how to integrate chemotherapy into the treatment of prostate cancer in the era of "targeted" alternative Chris Logothetis Advanced Cancer: The improved understanding of the immunobiology of prostate cancer; and its clinical application Padmanee Sharma</p>		<p>CLINICAL QUESTIONS FOR HODGKIN LYMPHOMA Chair: Volker Diehl Speakers: The role of PET/CT in directing the treatment of advanced HL Andrea Gallamini The current position of radiotherapy in early stages HL Theodore Girinsky The clinical relevance of the CD68+ macrophages in HL Christian Steidl*</p>	
	UROGENITAL CANCER		HAEMATOLOGICAL MALIGNANCIES	
13.15-14.30	<p>SCIENTIFIC SYMPOSIUM Neuroendocrine tumours Chair: Elisabeth De Vries Speakers: In the land of interferon for neuroendocrine tumours. Is interferon old or new? Kjell Oberg mMTor inhibition and beyond as novel treatment of neuroendocrine tumours James Yao* Novel approach with angiogenesis inhibitors for neuroendocrine tumours Eric Raymond</p>		<p>SCIENTIFIC SYMPOSIUM New developments; image guided therapy Chair: Patricia Price Speakers: Irreversible electroporation using Nanoknife and advance in radiofrequency ablation Edward Leen HIFU for a range of tumours Rick Popert title to be announced Anders Wennborg</p>	
	NO CATEGORY		NOVEL THERAPEUTICS	
14.30-15.30	LUNCH BREAK			
15.30-17.00	<p>CURRENT ISSUES IN ONCOLOGY Multiple Myeloma Chair: Alan Burnett Speakers: Current treatment expectations Paul Richardson* How to assess new treatments Peter Sonneveld* The role of transplantation Keith Stewart Risk adapted approaches Faith Davies Prognostic factors Jean-Luc Harousseau*</p>		<p>CURRENT ISSUES IN ONCOLOGY Loco-regional oesophageal cancer Chair: Peter Schlag Speakers: Squamous cell vs adenocarcinoma Peter Malfertheiner* Surgery alone Steven R DeMeester Neo-adjuvant/adjuvant chemotherapy Peter Schlag Definitive radiotherapy/chemoradiotherapy Jean-Francois Bosset*</p>	
	HAEMATOLOGICAL MALIGNANCIES		GASTROINTESTINAL (NON COLORECTAL)	
17.00-19.00	SPONSORED SATELLITE SYMPOSIA			

FRIDAY 24 FEBRUARY 2012

	HALL I	HALL II	HALL III	HALL IV
	Group B	Group A	Group D	Group C
8.30-9.30	CLINICAL CASE WORKSHOP Decision making in the treatment of recurrent ovarian cancer Moderator: Jonathan Ledermann Discussants: Management of end-stage recurrent ovarian cancer Marcia Hall About surgical aspects of recurrent ovarian cancer treatment Philipp Harter	CLINICAL CASE WORKSHOP Management of 1st line NSCLC after 4 cycles chemotherapy and stable disease Moderator: Sanjay Popat Discussants: to be announced	CLINICAL CASE WORKSHOP Decision making in prostate cancer progressing on ADT Moderator: Chris Logothetis Discussants: to be announced	CLINICAL CASE WORKSHOP Breast cancer Moderator: Stephen Johnston Discussants: to be announced
09.30-10.15	IPOS SPECIAL SESSION Current Issues in Oncology Assessment and Management of Delirium in cancer patients Chair: William Breitbart		ACS SPECIAL SESSION Current Issues in Oncology Update on Screening in Lung and Cervical cancer Chair: to be announced	
10.15-11.00				NSABP SPECIAL SESSION Milestone research of NSABP Speaker: Norman Wolmark
	PSYCHO-ONCOLOGY		SCREENING	
11.00-11.30	COFFEE BREAK			
11.30-12.30	EDUCATIONAL SYMPOSIUM Tumour Immunology Chair: Alexander Eggermont New insights in the role of the immune system in cancer Cees Melief* Chemotherapeutics, Targeted Drugs and Immunogenic Cell Death: the promise of synergy Laurence Zitvogel* New insights for developments of cancer vaccines Giorgio Parmiani* Melanoma, the paradigm tumor for new immunotherapeutic development strategies Alexander Eggermont		CLINICAL QUESTIONS FOR SURGERY IN METASTATIC CANCER Chair: to be announced Speakers: Kidney Cancer; should the primary be resected? to be announced Breast Cancer; should the primary be resected? to be announced GI Cancer; should the primary be resected? to be announced	
12.30-13.30			SURGICAL ONCOLOGY CLINICAL QUESTIONS FOR PROSTATE CANCER - SESSION II Chair: Chris Logothetis Speakers: Intermittent vs Continuous androgen ablation Laurence Klotz* and Chris Logothetis Immediate treatment vs Watchful waiting Chris Logothetis and Laurence Klotz*	
	IMMUNOLOGY WORKSHOP SESSION		UROGENITAL	
13.30-14.30	The direction of molecular imaging for the clinic in the next 5-10 years Chair: Gordon McVie Speakers: Labelling of bifunctional antibodies-dock and lock to unlock the potential of molecular imaging David Goldenberg What we have learnt from combining diagnostic and therapeutic molecular imaging Elizabeth DeVries* Why has PET failed to achieve its full potential Terry Jones			
	NOVEL THERAPEUTICS			
14.30-15.30	LUNCH BREAK			
15.30-16.30	SCIENTIFIC SYMPOSIUM Lymphomas/Hodgkin Lymphoma Chair: Magnus Björkholm Speakers: Hodgkin Lymphoma Andreas Engert Indolent lymphomas/Follicular lymphomas Gilles Salles* Diffuse Large Cell B cell Lymphomas David Linch* Auto-allografting in Lymphoma Anna Sureda		CLINICAL QUESTIONS FOR THORACIC ONCOLOGY Chair: Sanjay Popat Speakers: Current management of advanced neuroendocrine-differentiated NSCLC Lee Krug* Current systemic therapy for mesothelioma Paul Baas The role of stereotactic radiotherapy Suresh Senan*	
16.30-17.30			THORACIC ONCOLOGY CLINICAL QUESTIONS FOR OVARIAN CANCER Chair: Jonathan Ledermann Speakers: New pathology of ovarian cancer and biomarker driven research Robert Kurman* PARP inhibitors in ovarian cancer Jonathan Ledermann Treatment of endometrial cancer; role of systemic therapy and radiation Nick Reed*	
	HAEMATOLOGICAL MALIGNANCIES		GYNAECOLOGICAL CANCER	
17.30-19.30	SPONSORED SATELLITE SYMPOSIA			

SATURDAY 25 FEBRUARY 2012

	HALL I Group B	HALL II Group A	HALL III Group D	HALL IV Group C
8.30-9.30	MEET THE EXPERT SESSION Novel targets in mCRC; molecular based decision making, platforms for innovative designs Speaker: Scott Kopetz	KEYNOTE LECTURE Prevention and management of venous thrombosis in cancer patients Speaker: Kelvin Hong	MEET THE EXPERT SESSION New trends in chemotherapy of sarcomas Speaker: Jean-Yves Blay	MEET THE EXPERT SESSION Lynch syndrome/mismatch repair genes and choice of Chemotherapy Speaker: Astrid Stormorken
	NOVEL THERAPEUTICS	HAEMATOLOGICAL MALIGNANCIES	SARCOMAS	GENETICS
9.30-11.00	CURRENT ISSUES IN ONCOLOGY Peritoneal Carcinomatosis Chairs: Dirk Arnold and Pompiliu Piso Speakers: Colorectal Cancer Pompiliu Piso Gastric Cancer Olivier Glehen* Ovarian Cancer Deborah Kay Armstrong* Pseudomyxoma peritonei Brendan J. Moran Multimodal palliative treatment with intraperitoneal administration of monoclonal antibodies Dirk Arnold		CLINICAL QUESTIONS FOR RADIOTHERAPY Chair: Harry Bartelink Speakers: The role of micro arrays in predicting radiotherapy outcome Marc van de Vijver The role of biological agents in combination with Radiotherapy Eric Deutsch* The role of hypoxia in radiation oncology Jens Overgaard* The role of image guided radiotherapy to be announced	
	SURGICAL ONCOLOGY		RADIATION ONCOLOGY	
11.00-11.30	COFFEE BREAK			
11.30-12.30	CLINICAL QUESTIONS FOR BREAST CANCER Chair: Stephen Johnston Speakers: Will PARP inhibitors work for triple negative breast cancer? Andy Tutt* Can gene arrays provide helpful information for the treatment of breast cancer? Fatima Cardoso What is the role of PET imaging in the treatment of advanced breast cancer? Pat Price Which patients need adjuvant taxanes? Paul Ellis* Is tamoxifen still a useful drug, and if so for whom? Kathy Pritchard		CLINICAL QUESTIONS FOR CNS TUMOURS Chair: Evanthia Galanis Speakers: What is new in the management of CNS lymphoma? Patrick Wen What is new in the management of gliomas? Evanthia Galanis What is new in the management of CNS metastases? David Reardon*	
	BREAST CANCER		NEURO-ONCOLOGY	
12.30-13.15	KEYNOTE LECTURE Practice applied genomics Speaker: Norman Wolmark		SCIENTIFIC SYMPOSIUM The concept of genetic susceptibility and the screening of high risk individuals Chair: Angelo Paradiso Speakers: Who to screen? Bernardo Bonanni* Treatment of hereditary breast cancer Alain Fourquet Genetic counselling Silvia Formenti Round table discussion	
13.15-14.00	DEBATE Do angiogenesis inhibitors add anything but cost to current treatment of breast cancer? Moderator: Paul Ellis Speakers: PRO Norman Wolmark CON David Miles*			
	NOVEL THERAPEUTICS		GENETICS (& SCREENING)	
14.00-15.00	LUNCH BREAK			
15.00-16.00	CLINICAL QUESTIONS FOR LIVER METASTASES IN COLON CANCER Chair: Dirk Arnold Speakers: Surgery alone is the treatment of choice Ulf Neumann* The role of perioperative treatment Bernard Nordlinger* The role of adjuvant treatment Cornelis Punt*		CLINICAL QUESTIONS FOR MELANOMA Chair: Keith Flaherty Speakers: Is it time for the incorporation of BRAF targeted therapies into standard practice? James Larkin What is the role of novel immunotherapy in the treatment of melanoma? Caroline Robert* Is a history of ulcerated primary melanoma the only indication for adjuvant interferon therapy? Lex Eggermont	
	GASTROINTESTINAL CANCER (COLORECTAL)		MELANOMAS	

*: pending reply